Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 1/20 | 0.60 |
| ▸ | FLT4 | P35916 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7984974 | 0.85 | L3MBTL1 (0.59) | FLT1FLT4KDRL3MBTL1SMN1; SMN2 | |
| SCHEMBL17336774 | 0.81 | KDM4E (0.64) | FLT1FLT4KDRL3MBTL1SMN1; SMN2 | |
| SCHEMBL31305679 | 0.81 | KDM4E (0.64) | FLT1FLT4KDRL3MBTL1SMN1; SMN2 | |
| SCHEMBL7989112 | 0.81 | L3MBTL1 (0.59) | FLT1FLT4KDRL3MBTL1SMN1; SMN2 | |
| SCHEMBL2159159 | 0.81 | PKM (0.51) | L3MBTL1MEN1KMT2A | |
| SCHEMBL280256 | 0.81 | HDAC8 (0.68) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL13331743 | 0.81 | KDM4E (0.65) | MEN1KMT2ANPC1ALDH1A1RAB9A | |
| SCHEMBL20178561 | 0.80 | KAT6A (0.58) | ALDH1A1KAT6AGAA | |
| SCHEMBL22097515 | 0.79 | HDAC1 (0.50) | SMN1; SMN2ALDH1A1GRM5KAT6A | |
| SCHEMBL7990892 | 0.79 | HDAC1 (0.66) | L3MBTL1MEN1KMT2ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230359119-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| US-7241763-B2 | 3-furanyl analogs of toxoflavine as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| EP-1523485-B1 | 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-14 | — | — | EP | disclosed |
| US-20060040943-A1 | 3-Furanyl analogs of toxoflavine as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
| EP-1523485-A1 | 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004007499-A1 | 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | WO | disclosed |
| US-6331628-B1 | REACTING A SUBSTITUTED HALOBENZENE WITH POTASSIUM, SODIUM AND/OR ZINC CYANIDE IN THE PRESENCE OF A METALLIC CATALYST | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | FLT1 4750/4885FLT4 4807/4885KDR 4837/4885 |
| US-20060040943-A1 | 3-Furanyl analogs of toxoflavine as kinase inhibitors | GRK3, GRK4, GRK6 | FLT1 2109/4885FLT4 914/4885KDR 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.